Sign In
Buy VIR
$8.77
+0.0300 (+0.343%)
At Close: Jun 03, 2026
SAN FRANCISCO--(BUSINESS WIRE)---- $VIR #HBV--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will be presenting new data from its Phase 2 trials evaluating the potential clinical impact
Vir Biotechnology, Inc. (VIR) Q3 2023 Earnings Call Transcript
09:42pm, Thursday, 02'nd Nov 2023
Vir Biotechnology, Inc. (NASDAQ:VIR ) Q3 2023 Results Conference Call November 2, 2023 4:30 PM ET Company Participants Sasha Damouni Ellis - Executive Vice President, Chief Corporate Affairs Officer M
GSK Beats on Q3 Earnings and Sales, Raises 2023 Guidance
12:47pm, Wednesday, 01'st Nov 2023
GSK's revenues benefit from strong growth across the Specialty Medicines and Vaccines segments. The company raises guidance for earnings and sales on the back of strong RSV vaccine sales.
3 Bill Gates Stocks to Buy for Billionaire-Like Returns
12:31pm, Friday, 27'th Oct 2023
When investors think of Bill Gates stocks, they inevitably come up with Microsoft (NASDAQ: MSFT ), the software company he co-founded with Paul Allen in 1975 in Albuquerque. However, as Gates has spen
7 Biotech Stocks to Get In Now Before Investors Catch On
02:50am, Monday, 23'rd Oct 2023
Biotechnology is the source of some of our strongest and growing revolutions. Gene technology allows us to cure incurable diseases and make miracles happen with living organisms.
Vir Biotechnology to Provide Business Update and Report Third Quarter 2023 Financial Results on November 2, 2023
04:30pm, Thursday, 05'th Oct 2023
SAN FRANCISCO, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter en
Vir Biotech faces steep decline, Bank of America warns amid trial setbacks
02:41pm, Friday, 08'th Sep 2023
Vir Biotechnology Inc has faced a tough year so far, with shares declining by 54% year-to-date. Much of the company's underperformance is attributed to unimpressive results from both influenza A and h
Is Vir Biotechnology Stock a Buy?
10:15am, Friday, 11'th Aug 2023
Vir Biotechnology's coronavirus treatment is losing steam. The company's pipeline looks somewhat promising on first glance.
Vir Biotechnology, Inc. (VIR) Q2 2023 Earnings Call Transcript
10:55pm, Thursday, 03'rd Aug 2023
Vir Biotechnology, Inc. (NASDAQ:VIR ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Sasha Damouni Ellis - EVP and Chief Corporate Affairs Officer Marianne De Backer -
Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Misses Revenue Estimates
07:31pm, Thursday, 03'rd Aug 2023
Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $1.45 per share versus the Zacks Consensus Estimate of a loss of $1.21. This compares to loss of $0.58 per share a year ago.
Vir Biotechnology (VIR) Down on Influenza Study Failure
01:42pm, Friday, 21'st Jul 2023
Vir Biotechnology (VIR) crashes after the phase II study evaluating VIR-2482 for preventing symptomatic influenza A illness fails to meet goals.
Vir Biotech slumps to over 3-year low as flu prevention therapy fails trial
12:37pm, Thursday, 20'th Jul 2023
Vir Biotechnology's shares plunged 45% to a more than three-year low on Thursday after the company's experimental antibody therapy to prevent a type of flu failed to meet its goals in a mid-stage tria
Why Shares of Vir Biotechnology Are Plunging Thursday
11:31am, Thursday, 20'th Jul 2023
Vir Biotechnology has seen declining revenue because sales of its one marketed product, Sotrovimab, are declining. A phase 2 trial for an influenza A therapy didn't meet primary or secondary endpoints
Vir Biotechnology says mid-stage trial of a flu treatment failed to meet main goals
08:10am, Thursday, 20'th Jul 2023
Vir Biotechnology Inc. VIR, +0.92% said Thursday a mid-stage trial of a treatment for symptomatic flu failed to meet its main goals. The Phase 2 trial dubbed Peninsula was evaluating VIR-2482 for the
Vir Biotechnology to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference
04:05pm, Monday, 05'th Jun 2023
SAN FRANCISCO, June 05, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to participate
